Meet Senzime at Medica Trade Fair in Düsseldorf, 13-16 November

Uppsala, November 8, 2017. Medica Trade Fair in Düsseldorf is the world's leading trade fair for the medical industry. The fair consists of 17 halls where exhibitors from all over the world will present their products. Welcome to meet Senzime at Medica to learn more about our patient monitoring products OnZurf Probe, CliniSenz Analyzer and TetraGraph.

Senzime is co-exhibiting with Business Sweden in Hall 3A/3AE29 .

Please book a meeting with us – s end an email to: info@senzime.com  

When: 13-16 November 2017

More info about Senzime at Medica .

For further information, please contact:

Pernilla Abrahamsson, Marketing and Sales Director
Tel:
+46-70-37 37 472 ,

pernilla.abrahamsson@senzime.com  

TO THE EDITORS

About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime.  www.senzime.com

Tags:

About Us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com

Subscribe

Media

Media

Documents & Links